|Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis.|
|Jump to Full Text|
|PMID: 23018346 Owner: NLM Status: MEDLINE|
|BACKGROUND: There is a great need for developing novel therapies to treat liver fibrosis. Previous studies showed that both Smad7 and uPA were inhibitors of liver fibrosis. Therefore, we explored the therapeutic effects of combinational gene therapy with Smad7 and uPA on CCl4-induced liver fibrosis.
MATERIAL/METHODS: Smad7 and uPA genes were cloned into an adenovirus vector. To observe the therapeutic effects of coexpression of Smad7 and uPA genes, the recombinant adenovirus were delivered into CCL4-induced fibrosis models. Fibrillar collagen, hydroxyproline, α-SMA, TGF-β1, MMP-13, TIMP-1, HGF and PCNA were detected to evaluate the fibrosis and to explore the mechanisms underlying the treatment with Smad7 and uPA.
RESULTS: The results showed that single Smad7 or uPA adenovirus reduced CCL4 induced liver fibrosis significantly; while combination of Smad7 and uPA had more significant therapeutic effect on CCl4 induced liver fibrosis. Then the markers underlying the therapeutic effect of combination of Smad7 and uPA were also explored. Over-expression of Smad7 and uPA inhibited the expression of α-SMA and TGF- β1 significantly. Combinational gene therapy also enhanced extracellular matrix degradation by increasing the expression of MMP-13, inhibiting TIMP-1 expression, and promoted hepatocyte proliferation, while single Smad7 or uPA only induced part of these changes.
CONCLUSIONS: These results suggest that combinational gene therapy with Smad7 and uPA inhibited CCl4-induced rat liver fibrosis by simultaneously targeting multiple pathogenic pathways.
|Baocan Wang; Wenxi Li; Yingwei Chen; Yuqin Wang; Chao Sun; Yuanwen Chen; Hanming Lu; Jiangao Fan; Dingguo Li|
Related Documents :
|24748426 - The transcription factor chop, a central component of the transcriptional regulatory ne...
23849466 - Modulation of stress related protein genes in the bass (epinephelus guaza) caught from ...
23817206 - Adeno-associated virus-mediated rescue of neonatal lethality in argininosuccinate synth...
24811296 - Familial combined hyperlipidemia: from molecular insights to tailored therapy.
3288646 - Mechanism of induction of class i major histocompatibility antigen expression by murine...
20626746 - Current and future pharmacological treatment strategies in x-linked adrenoleukodystrophy.
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: Medical science monitor : international medical journal of experimental and clinical research Volume: 18 ISSN: 1643-3750 ISO Abbreviation: Med. Sci. Monit. Publication Date: 2012 Oct|
|Created Date: 2012-09-28 Completed Date: 2013-02-19 Revised Date: 2013-07-11|
Medline Journal Info:
|Nlm Unique ID: 9609063 Medline TA: Med Sci Monit Country: Poland|
|Languages: eng Pagination: BR394-401 Citation Subset: IM|
|Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.|
|APA/MLA Format Download EndNote Download BibTex|
Extracellular Matrix / metabolism
Gene Expression Regulation, Enzymologic
Hepatocytes / metabolism, pathology
Liver / metabolism, pathology
Liver Cirrhosis / chemically induced, enzymology, pathology*, therapy*
Matrix Metalloproteinase 13 / genetics, metabolism
RNA, Messenger / genetics, metabolism
Recombination, Genetic / genetics
Smad7 Protein / genetics, metabolism, therapeutic use*
Tissue Inhibitor of Metalloproteinase-1 / genetics, metabolism
Transforming Growth Factor beta1 / metabolism
Urokinase-Type Plasminogen Activator / genetics, metabolism, therapeutic use*
|0/RNA, Messenger; 0/Smad7 Protein; 0/Smad7 protein, rat; 0/Tissue Inhibitor of Metalloproteinase-1; 0/Transforming Growth Factor beta1; 56-23-5/Carbon Tetrachloride; EC 220.127.116.11/Urokinase-Type Plasminogen Activator; EC 3.4.24.-/Matrix Metalloproteinase 13|
Journal ID (nlm-ta): Med Sci Monit
Journal ID (iso-abbrev): Med. Sci. Monit
Journal ID (publisher-id): Medical Science Monitor
Publisher: International Scientific Literature, Inc.
© Med Sci Monit, 2012
Received Day: 08 Month: 1 Year: 2012
Accepted Day: 21 Month: 5 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 01 Month: 10 Year: 2012
Volume: 18 Issue: 10
First Page: BR394 Last Page: BR401
PubMed Id: 23018346
Publisher Id: 883479
|Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis|
1Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
2China Novartis Institutes for BioMedical Research Co. Ltd., Shanghai, China
|Correspondence: Jiangao Fan, Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China, e-mail: email@example.com and Dingguo Li, Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China, e-mail: firstname.lastname@example.org
*These authors contributed equally to this work
Liver fibrosis is a wound-healing response caused by reiterated liver tissue injury due to hepatitis B virus or hepatitis C virus infection, alcohol abuse, nonalcoholic steatohepatitis, toxin/drug-induced injury, and autoimmune damage. The main characteristic of liver fibrosis is the excessive accumulation of extracellular matrix (ECM) proteins, including collagens I and III, fibronectin, laminin, and proteoglycans. Advanced liver fibrosis leads to liver cirrhosis, which is a major cause of mortality and a worldwide public health challenge. Liver fibrosis involves a complex mechanism by which tissue injury factors activate fibrogenetic cells, especially hepatic stellate cells (HSC), to proliferate and secrete ECM proteins, cytokines, and enzymes. All of these alterations lead to increased ECM protein deposition, decreased ECM degradation, and impaired hepatocyte function . Therefore, the ideal antifibrotic strategy to treat liver fibrosis should include inhibition of fibrogenesis, acceleration of fibrolysis, and stimulation of hepatocyte regeneration. Currently, no drugs are available to inhibit liver fibrosis completely; therefore, a gene therapy strategy represents a novel therapeutic approach to treat liver fibrosis. The majority of gene therapy strategies tested for the treatment of liver fibrosis used only a single gene to inhibit the fibrotic process; however, since the pathogenesis of liver fibrosis is multifaceted and involves multiple pathways and genes, it is likely that a combined 2-gene approach, which targets 2 separate pathways involved in liver fibrosis, will be more effective than a single-gene treatment. Thus, we investigated the antifibrotic effects of a 2-gene therapeutic approach in this study.
Many profibrogenic cytokines are involved in liver fibrosis, among which TGF-β1 plays a pivotal role in initiating and sustaining the fibrogenesis of the liver . Transgenic mice that overexpress active human TGF-β1 develop severe fibrosis of the liver . TGF-β1 contributes to liver fibrosis in 2 ways: (1) by increasing ECM deposition, and (2) by protecting the matrix from degradation and inducing hepatocyte apoptosis . TGF-β1 downregulates the expression of several matrix metalloproteinases (MMPs), including MMP-1  and MMP-9 , and upregulates the expression of both tissue inhibitor of metalloproteinases 1 (TIMP-1)  and plasminogen activator inhibitor-1 (PAI-1) . The intracellular signal transduction of TGF-β1 is mediated by Smad proteins. After being phosphorylated by the activated TGF-β type I receptor (TGFβRI), Smad2 and Smad3 form a complex with Smad4, and this complex translocates into the nucleus where it acts as a transcriptional activator of target genes. In contrast, Smad7 is a negative regulator of this signaling pathway . However, in activated HSCs, TGF-β1-induced Smad7 expression is diminished . Therefore, upregulating Smad7 expression may inhibit TGF-β1-induced fibrogenesis, which has been shown to occur in the liver, lung, and kidney.
Recently, the urokinase plasminogen activator (uPA) system, consisting of the serine protease uPA, its inhibitors (PAI-1 and PAI-2), and receptor [urokinase plasminogen activator receptor (uPAR)], has also been implicated in the inhibition of liver fibrosis. Originally, uPA was thought to be a serine protease that converted inactive plasminogen into active plasmin, which can degrade ECM components directly or indirectly by activating the MMPs. However, new data suggest that uPA also participates in cell proliferation, adhesion, migration, and angiogenesis by interacting with the uPAR in a plasmin-independent manner [11,12]. Ligation of the uPAR activates growth factors, such as fibroblast growth factor-2 (FGF2), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), and hepatocyte growth factor (HGF) [13,14]. Recently, studies of knockout mice with an inactive uPA system indicated that uPA and plasminogen play a critical role in the liver repair process after injury. uPA gene knockout (uPA−/−) mice had abnormally high fibrogenesis, developing fibrin deposits in the skin, gastrointestinal tract, and the hepatic sinusoids . The roles of uPA and plasminogen have also been investigated in rats using carbon tetrachloride-(CCl4) or Fas-induced acute liver injury. In CCl4 induced acute liver injury, lack of uPA  or plasminogen  led to the accumulation of fibrin and fibronectin within injured areas, insufficient removal of necrotic cells, and delayed repair. Similarly, after Fas-induced liver injury, uPA−/− mice show delayed HGF maturation and hepatic regeneration . Plasminogen deficiency also leads to excessive matrix accumulation and prominent activation of HSCs after chronic liver injury . Further, PAI-1-deficient mice show accelerated wound closure . In cultured HSC  and cirrhotic liver , there is decreased uPA expression concomitant with an increase in PAI-1 expression, which leads to low uPA activity and failure to resolve the fibrotic scarring.
Since both Smad7 and uPA are important inhibitors in liver fibrosis, then simultaneously increasing Smad7 and uPA expression in fibrotic liver tissues may inhibit liver fibrosis by inhibiting 2 different pathways involved in fibrotic damage. Adenovirus based vectors are the most popular vectors for gene therapy to treat the liver diseases, including liver fibrosis; however, high doses of adenovirus can cause severe adverse effects, including hepatic injury . Thus, development of a single adenovirus vector for the expression of both Smad7 and uPA is a superior strategy to the use 2 separate vectors. Recently, bicistronic adenoviral vectors, utilizing an internal ribosome entry site (IRES) to direct the expression of 2 heterologous genes, have gained broad use . In this study, we investigated the therapeutic effects of a bicistronic adenovirus vector co-expressing Smad7 and uPA to treat liver fibrosis and the possible mechanisms targeted by these 2 genes to limit fibrogenesis.
The recombinant adenovirus was constructed with routine molecular cloning techniques. Briefly, the cDNA fragments of rat Smad7 and uPA were obtained from pTSmad7 and kidney RNA, respectively. The Smad7 and uPA cDNA were inserted into multiple cloning site (MCS) A and MCS B of the pIRES plasmid, respectively (Clontech, CA, USA). The pIRES plasmid contains an IRES from the encephalomyocarditis virus (ECMV), which allows translation of 2 consecutive open reading frames from the same messenger RNA (mRNA) [25,26]. Then, the bicistronic Smad7 and uPA expression cassette (Smad7-IRES-uPA) was inserted into an adenoviral shuttle plasmid. Following co-transformation of BJ5138 E. coli with the backbone plasmid, Adeasy-1, and the shuttle plasmid, the adenoviral plasmid carrying Smad7 and uPA was generated by homologous recombination and the adenovirus was packaged in AD-293 cells (Stratagene, CA, USA). The adenovirus carrying Smad7, uPA or Smad7 and uPA were named as AdSmad7, AduPA, or AdSmad7-uPA, respectively. The recombinant adenovirus was purified by CsCl gradient centrifugation, and dialyzed against phosphate-buffered saline (PBS) plus 10% glycerol. The viral titers were determined by an end-point dilution assay. The adenovirus vectors AdGFP was used as controls. Correct construction of the vectors were determined by restriction enzyme digest and sequencing.
The L02 human hepatocyte cell line was seeded at 1×105/cm2 and cultured for 24 h, then transduced with AdSmad7-uPA, AdSmad7, AduPA, at multiplicity of infection (MOI) of 20 particles per cell in minimal DMEM with 5% fetal bovine serum (FBS) for 4 h. The cells were then maintained in serum-free DMEM for 48 h. Cell lysates and supernatant serum-free medium were collected and stored at −80°C for later analysis.
Smad7, TGF-β1, α-SMA and HGF-β protein expression levels were examined by immunoblot as described previously . Cells and liver tissues were lysed in RIPA buffer, which contained 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and protease inhibitors, at 4°C, followed by centrifugation at 1000g for 30 minutes. The supernatant was collected and the protein concentration determined using the BCA assay. Protein samples (20 μg) were resolved by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, USA) using a semi-dry transfer cell. The membrane was blocked in 5% nonfat milk in Tris-buffered saline plus 0.1% Tween 20 (TBST), and incubated with a Smad7-specific antibody (Santa Cruz Biotechnology, CA, USA) diluted 1: 1,000, HGF-β-specific antibody diluted 1:1,000 (Santa Cruz Biotechnology, CA, USA), TGF-β1 antibody diluted 1:1000 (Cell signaling Technology, MA, USA), α-SMA antibody diluted according to manual (SIGMA, MO, USA) or β-actin-specific antibody diluted 1:2,000 (Santa Cruz Biotechnology, USA) overnight at 4°C. The membranes were then incubated with the appropriate HRP-conjugated secondary antibodies and the proteins visualized using an enzyme chemiluminescence (ECL) detection system (Pierce, Rockford, IL, USA). Band intensities were quantified using Quantity One 4.6.2 analysis software.
uPA secretion in cell culture supernatants and liver tissues was measured using a rat uPA ELISA kit according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN).
Proteolytic activity of the recombinant uPA was shown by zymography as described previously . The media samples were separated by SDS-PAGE on 12% gels containing α-casein (7 mg/ml) and human glu-plasminogen (Sigma, St. Louis, MO, USA, 20 mg/ml). The gels were then washed in 1% Tween 80 for 1 h at 37°C and subsequently incubated in PBS containing 0.1% Tween 80 overnight at room temperature. Then the gels were stained with Coomassie blue and destained in a solution of 10% acetic acid and 50% methanol. The bands displaying proteolytic activity were determined by comparison with protein molecular weight marker.
Male Sprague-Dawley rats weighing 200 to 250 g were used in this study. All animal experiments were performed in accordance with our institutional guidelines. Liver fibrosis was induced by injecting CCl4 subcutaneously (3 ml/kg as a 2:3 mixture with olive oil) every 3 days for a total of 8 weeks and mock-treated animals were injected with olive oil alone as a negative control. At 2 and 4 weeks after the first CCl4 injection, 0.5 ml (5×109 pfu) AdSmad7-uPA, AdSmad7, AduPA, AdGFP, or saline (control group) was injected into the tail veins of 11 rats per group. To examine the efficiency of adenoviral gene transfer to the liver, 3 days after the first injection of adenovirus, liver tissue samples were obtained randomly from 3 rats injected with AdSmad7-uPA, AdSmad7, AduPA, or AdGFP. The remaining animals were euthanized at the ninth week, and liver tissues were collected. The liver tissue samples of the right median lobe were snap-frozen in liquid nitrogen or fixed in 10% buffered formalin.
The liver tissues were fixed and embedded in paraffin. Five-micrometer sections were stained with hematoxylin-eosin and 0.1% Sirius red in saturated picric acid . Immunohistochemical staining was performed by dewaxing slides in xylene and dehydrating in alcohol. Antigen retrieval was achieved by a 500-W microwave, heating the sections in citric saline for 15 min. After blocking endogenous peroxidases by 3% hydrogen peroxide for 10 minutes, sections were incubated with anti-Smad7 antibody diluted 1:400 (Santa Cruz Biotechnology, CA, USA), α-smooth muscle actin (α-SMA) antibody diluted 1:500 (Santa Cruz Biotechnology, USA), TGF-β1 antibody diluted 1:400 (Santa Cruz Biotechnology, USA), and proliferating cell nuclear antigen (PCNA) antibody diluted 1:300 (Boster, Wuhan, China) for 1 h at room temperature. After washing in PBS, sections were incubated with the appropriate peroxidase-conjugated secondary antibody for 20 min. Positive staining visualized using 3, 3′-diaminobenzidine tetrahydrochloride (DAB). Quantitative analysis of fibrosis and immunopositive cell area was carried out with the Image-Pro plus image software in 5 microscopic fields of specimens taken from 8 rats.
Liver tissue (100 mg) samples were subjected to acid hydrolysis to determine the amount of hydroxyproline, as previously described . The hydroxyproline content was indicated as micrograms per gram of wet liver.
Total RNA was extracted from the liver with chloroform and Trizol reagent (Invitrogen, Carlsbad, CA, USA), and cDNA was generated by reverse-transcription using random primers. Real-time PCR was performed as described previously  using ABI prism 7100 Sequence Detector (Applied Biosystems, Foster City, CA, USA). Sequences of the primers for MMP-13 and TIMP-1 were: MMP-13: forward- ACCCCAAAACACCAGAGAAGTGT, reverse- GGAAGTTCTGGCCAAAAGGACT; TIMP-1: forward- TCCTGGTTCCCTGGCATAATCT, reverse- AGCCCATGAGGATCTGATCTGTC. PCR was performed using SYBR green technology in a final volume of 25 μl. Briefly, 100 ng (5 μl) of cDNA was mixed with 12.5 μl of SYBR-green master mix (Roche Diagnostics, CA, USA) and 0.5 μl of each primer (10 pmol/μl). Condition was: 95°C for 5 min (initial denaturation), 95°C for 15 s, and 62°C for 20 s (45 cycles). For each amplification curve, the threshold cycle was determined for calculating the relative amount of target RNA using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control.
Experiments were performed in triplicate, and results are expressed as the means ± standard deviation (SD). A 1-way analysis of variance (ANOVA) was used for statistical comparisons and P value less than 0.05 were considered statistically significant.
Adenoviral vectors encoding Smad7, uPA, or Smad7 and uPA were constructed as described in Material and Methods. Recombinant adenoviruses were generated after transfection of pAdSmad7, pAduPA, or pAdSmad7-uPA into AD-293 cells, and plaques from the first and final rounds of amplification were identified by PCR for the Smad7 and uPA genes (data not shown). After adenoviral infection, the level of Smad7 protein in L02 cells infected with AdSmad7-uPA was similar to cells infected with the AdSmad7-positive control vector, and significantly higher than in cells infected with the AdGFP-negative control vector (Figure 1A).
The expression of recombinant uPA was determined by ELISA of the cell culture supernatants, and substantial amounts of uPA were secreted by AdSmad7-uPA or AduPA infected L02 cells, but uPA was not detected in the supernatants of AdGFP transduced cells (Figure 1D). Next, we tested the enzymatic activity of uPA expressed by AdSmad7-uPA using a zymography assay in vitro. As shown in Figure 1C, culture supernatants of L02 cells transduced with Adsmad7-uPA or AduPA yielded a 45-kDa band by zymography assay, indicating that the recombinant uPA expressed by the vector was active.
Further, the efficiency of intrahepatic expression of AdSmad7-uPA was analyzed by immunoblot (Figure 1B) and ELISA (Figure 1D). Three days after IV adenovirus injection, high level expression of Smad7 and uPA was detected in the livers of AdSmad7-uPA-treated animals; however, minimal detection of Smad7 and uPA was observed in the livers of AdGFP-treated animals. These results confirmed a sustained expression of Smad7 and uPA in liver tissues after IV injection of AdSmad7, AduPA, or AdSmad7-uPA.
In this study, advanced hepatic fibrosis and regenerating nodules were typically observed in rats treated with CCl4 every third day for 8 weeks (Figure 2). AdSmad7 or AduPA treatment could inhibit the deposition of fibrillar collagen, and further inhibition of collagen deposition was observed in AdSmad7-uPA-treated animals. Quantitative morphometric data showed that compared with the AdGFP-treated rats, fibrosis was significantly reduced by 31.71%, 30.47% and 61.49% in the AdSmad7 (P<0.05), AduPA-(P<0.05) or AdSmad7-uPA-(P<0.01) treated group, respectively (Figure 2A, B). As the hydroxyproline level in the liver is known to parallel the extent of fibrosis, next we measured the liver hydroxyproline content in each group. Compared with the AdGFP-treated animals, over-expression of Smad7 or uPA alone inhibited the hydroxyproline accumulation induced by CCl4 (P<0.05). Importantly, treatment with the combination of Smad7 and uPA led to a further statistically significant decrease of hydroxyproline accumulation (P<0.01). The concentrations of hydroxyproline in rat liver tissues treated with AdSmad7-uPA, AdSmad7, AduPA, and AdGFP were 407.81±106.3 μg/g, 577.43±123.3 μg/g, 617.41±97.24 μg/g and 868.85±67.69 μg/g, respectively (Figure 2C).
The activation of HSCs is the crucial event in liver fibrosis, and expression of SMA is commonly used to quantitate the number of activated HSCs . Also, activated HSCs are the most important source of TGF-β1, which plays a pivotal role in the deposition of ECM proteins. To further investigate the influences of Smad7 and uPA dual-gene therapy on activation of HSCs in vivo, we detected the expression of SMA and TGF-β1 in liver by immunohistochemical staining (Figure 3A) and Western immunoblot analysis (Figure 3B). Compared with the normal liver, the livers of CCl4-treated rats displayed markedly higher expression of α-SMA and TGF-β1. Single Smad7 or uPA gene therapy significantly suppressed α-SMA and TGF-β1 expression in the fibrotic liver of CCl4 treated rats (P<0.05 for both); however, combinational treatment with both Smad7 and uPA further inhibited α-SMA and TGF-β1 expression (P<0.01). As shown in Figure 3, compared with the AdGFP control vector, Smad7 treatment reduced the expression of α-SMA and TGF-β1 by 35.48% and 43.38%, respectively, uPA treatment only slightly reduced the expression of α-SMA and TGF-β1 expression (P>0.05 for both), and dual treatment with both Smad7 and uPA reduced the expression of α-SMA and TGF-β1 by 75% and 73.77%, respectively (Figure 3C). Thus, combined therapy reduced fibrosis more significantly than treatment with Smad7 or uPA alone. These results indicate that Smad7 and uPA treatment resulted in a additive effect to prevent the activation of the HSCs.
ECM degradation is mainly catalyzed by the matrix metalloproteinases (MMPs), and the interstitial collagenase MMP-13 is an important enzyme that degrades collagen I and III in the rats . The activities of MMPs are inhibited by tissue inhibitors of metalloproteinases-1 (TIMP-1). Liver fibrosis is characterized by downregulation of MMP activity and upregulation of TIMP-1 levels, which stabilizes the ECM components. In this study, we examined the MMP-13 and TIMP-1 mRNAs levels in the rat fibrotic livers induced by CCl4 by quantitative RT-PCR. The results indicate that TIMP-1 mRNA increased substantially, but MMP-13 mRNA levels only increased slightly, when liver injury was induced by CCl4. Although MMP-13 mRNA levels were not altered in AdSmad7-treated rat livers, there were 3.12-fold and 3.25-fold increases in AdSmad7-uPA-treated and AduPA-treated rats livers, respectively (P<0.01 for both). In addition, in the AdSmad7-uPA-treated rats, the TIMP-1 mRNA level was significantly less than in the AdGFP- or AdSmad7-treated rats (P<0.01 and P <0.05) (Figure 4). In uPA-treated rats, TIMP-1 mRNA level had a decreasing trend compared to AdGFP-treated rats (P>0.05).
It has been demonstrated that uPA is capable of converting the inactive form of pro-HGF into the active form, which stimulates hepatocyte proliferation. PCNA acts as an auxiliary protein of DNA polymerase-delta to initiate cell proliferation; therefore, the expression of PCNA is regarded as a marker for evaluating changes in cell proliferation . In this study, immunohistostaining analysis was used to detect the expression of PCNA to evaluate the proliferation of hepatocytes. Immunoblot analysis was performed to detect the expression of mature HGF in the livers using an antibody that recognizes only the active form of HGF-β. As shown in Figure 5, immunohistological analysis of liver sections showed PCNA expression in the AdSmad7-uPA- and AduPA-treated rats was 2.07-fold and 2.2-fold greater that in AdGFP-treated rats (P<0.01 for both), Similarly, mature HGF expression was higher in the AdSmad7-uPA- or AduPA-treated rats than that in AdGFP- or AdSmad7-treated rats (P<0.01 for both). No significant increase in HGF-β expression and PCNA-stained cells were observed in the AdSmad7-treated rats compared with AdGFP-treated rats.
Liver fibrosis is characterized by excessive extracellular matrix (ECM) components deposition by the increase of synthesis and the decrease of degradation. Thus, liver fibrosis therapy may focus on promoting ECM degradation and inhibiting ECM synthesis. Until now, no drugs could inhibit liver fibrosis completely; therefore, more endeavors in developing new therapy strategy were needed. In this study we made a new attempt to deliver genes into CCL4-induced rat liver fibrosis models. The results showed single uPA or single smad7 gene therapy could inhibit CCL4-induced fibrosis significantly, while these 2 genes in combination could attenuate liver fibrosis more obviously than either single uPA or single smad7, and the reduction in liver fibrosis was mediated by inhibiting ECM deposition, accelerating ECM degradation, and promoting hepatocyte proliferation. To our knowledge, this is the first report demonstrating the use of a bicistronic adenoviral vector to mediate a dual-gene expression therapy for liver fibrosis.
It is currently thought that the TGF-β1/Smad signaling pathway acts as a central pathway leading to liver fibrosis, regardless of the initial pathogenic causes in disease conditions. Smad7, an inhibitory Smad, acts in a negative feedback loop to inhibit TGF-β1 activity by preventing the phosphorylation of Smad2/3 . In rats injected with CCl4 for 8 weeks, inhibition TGF-β1 action by Smad7 alone led to partial reduction of liver ECM deposition, with no increase of metalloproteinase expression or hepatocyte proliferation. Similarly, inhibition of TGF-β1 expression or signaling by different approaches, such as antisense oligonucleotides, truncated TGF-β receptor, or ALK5 (the TGF-b type I receptor) inhibitor [36–38], only partially relieves liver fibrosis. Taken together, these results indicate that blocking TGF-β1 alone may miss other potentially major therapeutic targets for the treatment of liver fibrosis.
Extensive evidence supports the fact that the plasminogen activation system participates in the matrix remodeling process, and alterative expressions of the plasminogen activation system were found in fibrotic organs. Up to now, the antifibrotic activity of uPA was confirmed in animal models of liver and pulmonary fibrosis [27,39]. In this study we demonstrated that although single Smad7 gene therapy attenuates liver fibrosis, expression of both Smad7 and uPA significantly improves the therapeutic effects compared to single Smad7 or single uPA gene transfer. This is illustrated by the greater reduction in the extent of liver fibrosis, enhanced MMP-13 expression, and promotion of hepatocyte proliferation. Beyond the beneficial effects of expressing Smad7 and uPA alone, several cross-talk mechanisms may explain the increased efficacy of the combined therapy. First, previous experiments demonstrated that TIMP-1, which is primarily secreted by HSC, may reduce MMP activity and suppress apoptosis of HSCs . Thus, inhibition of HSC activation by Smad7 may enhance ECM degradation. Also, ECM degradation by uPA may alter ECM characters and cell-ECM interactions, which could facilitate HSC apoptosis and decrease ECM deposition . Furthermore, HGF activated by uPA could antagonize TGF-β1 directly, and inhibit ECM production . While all of these ideas are consistent with published data, the mechanisms by which Smad7 and uPA inhibit liver fibrosis remain to be defined.
In summary, combined gene therapy using Smad7 and uPA co-expression adenoviral vector inhibited CCl4-induced rat liver fibrosis by simultaneously targeting multiple pathogenic pathways. However, since overexpression of Smad7 and uPA in hepatocytes may lead to carcinogenesis  and can effect clotting, these concerns must be addressed before clinical application of this approach can be used to treat liver cirrhosis patients. It is possible that the use of cell- or tissue-specific promoters to restrict recombinant gene expression to HSCs may help to overcome these challenges . Future studies on the safety and efficacy of the next generation of adenoviral vectors are also needed to optimize these approaches for clinical applications, but our current study may provide a foundation for designing future therapeutic regimens for inhibiting the progression of chronic liver diseases in clinical settings.
fn9-medscimonit-18-10-br394Conflict of interest statement
The authors declare that there is no conflict of interest in this work.
fn10-medscimonit-18-10-br394Source of support: National Natural Science Foundation of China (Grant No: 30900671), Shanghai Natural Science Foundation (Grant No: 09ZR1419700)
We thank Qin-Fang Xu for technical assistance; Wen-Zhu Zhang for help with Histological and immunohistochemical detection; Ben-Shang Li for help with real-time PCR analysis.
|1.||Friedman SL. Evolving challenges in hepatic fibrosisNat Rev Gastroenterol HepatolYear: 2010784253620585339|
|2.||Matsuzaki K. Modulation of TGF-beta signaling during progression of chronic liver diseasesFront BiosciYear: 20091429233419273245|
|3.||Ueberham E,Low R,Ueberham U,et al. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosisHepatologyYear: 200337510677812717387|
|4.||Black D,Lyman S,Qian T,et al. Transforming growth factor beta mediates hepatocyte apoptosis through Smad3 generation of reactive oxygen speciesBiochimieYear: 2007891214647317936489|
|5.||Yuan W,Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3J Biol ChemYear: 200127642385021011502752|
|6.||Ogawa K,Chen F,Kuang C,Chen Y. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB siteBiochem JYear: 2004381Pt 24132215086314|
|7.||Akool el S,Doller A,Muller R,et al. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathwayJ Biol ChemYear: 200528047394031616183640|
|8.||Min AK,Kim MK,Seo HY,et al. Alpha-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-beta signaling pathwayBiochem Biophys Res CommunYear: 201039335364120153726|
|9.||Dooley S,Hamzavi J,Ciuclan L,et al. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damageGastroenterologyYear: 200813526425918602923|
|10.||Dooley S,Delvoux B,Lahme B,et al. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblastsHepatologyYear: 2000315109410610796885|
|11.||Mondino A,Blasi F. uPA and uPAR in fibrinolysis, immunity and pathologyTrends ImmunolYear: 20042584505515275645|
|12.||Smith HW,Marshall CJ. Regulation of cell signalling by uPARNat Rev Mol Cell BiolYear: 2010111233620027185|
|13.||Plouet J,Moro F,Bertagnolli S,et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effectJ Biol ChemYear: 19972722013390969148962|
|14.||Mars WM,Jo M,Gonias SL. Activation of hepatocyte growth factor by urokinase-type plasminogen activator is ionic strength-dependentBiochem JYear: 2005390Pt 13111515869463|
|15.||Carmeliet P,Schoonjans L,Kieckens L,et al. Physiological consequences of loss of plasminogen activator gene function in miceNatureYear: 19943686470419248133887|
|16.||Shanmukhappa K,Sabla GE,Degen JL,Bezerra JA. Urokinase-type plasminogen activator supports liver repair independent of its cellular receptorBMC GastroenterolYear: 200664017134505|
|17.||Currier AR,Sabla G,Locaputo S,et al. Plasminogen directs the pleiotropic effects of uPA in liver injury and repairAm J Physiol Gastrointest Liver PhysiolYear: 20032843G5081512431907|
|18.||Jiang D,Xu C,Li Z,et al. Protective action of hepatocyte growth factor on transforming growth factor beta-1-induced alpha-smooth muscle actin and extracellular matrix in cultured human peritoneal fibroblastsMed Sci MonitYear: 2010168BR2505420671605|
|19.||Pohl JF,Melin-Aldana H,Sabla G,et al. Plasminogen deficiency leads to impaired lobular reorganization and matrix accumulation after chronic liver injuryAm J PatholYear: 2001159621798611733368|
|20.||Chan JC,Duszczyszyn DA,Castellino FJ,Ploplis VA. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient miceAm J PatholYear: 2001159516818811696429|
|21.||Leyland H,Gentry J,Arthur MJ,Benyon RC. The plasminogen-activating system in hepatic stellate cellsHepatologyYear: 19962451172788903394|
|22.||Gonzalez-Cuevas J,Bueno-Topete M,Armendariz-Borunda J. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissueJ Gastroenterol HepatolYear: 2006211015445416928215|
|23.||Cotter MJ,Muruve DA. The induction of inflammation by adenovirus vectors used for gene therapyFront BiosciYear: 200510109810515769609|
|24.||Na M,Fan X. Design of Ad5F35 vectors for coordinated dual gene expression in candidate human hematopoietic stem cellsExp HematolYear: 20103864465220303383|
|25.||Rees S,Coote J,Stables J,et al. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant proteinBiotechniquesYear: 19962011024106108108770413|
|26.||Green NK,McNeish IA,Doshi R,et al. Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vectorInt J CancerYear: 200310411041212532426|
|27.||Piotrowski WJ,Górski P,Pietras T,et al. The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosisMed Sci MonitYear: 20111710CR59860721959615|
|28.||James J,Bosch KS,Aronson DC,Houtkooper JM. Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liverLiverYear: 1990101152308475|
|29.||Yoshiji H,Kuriyama S,Yoshii J,et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouseHepatologyYear: 2002364 Pt 18506012297832|
|30.||Lu P,Liu H,Yin H,Yang L. Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cellsMed Sci MonitYear: 2011179BR2485621873937|
|31.||Carpino G,Morini S,Ginanni Corradini S,et al. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantationDig Liver DisYear: 20053753495615843085|
|32.||Gressner AM. Cytokines and cellular crosstalk involved in the activation of fat-storing cellsJ HepatolYear: 199522Suppl 228367665846|
|33.||Hironaka K,Sakaida I,Matsumura Y,et al. Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosisBiochem Biophys Res CommunYear: 200026712909510623612|
|34.||Apte UM,McRee R,Ramaiah SK. Hepatocyte proliferation is the possible mechanism for the transient decrease in liver injury during steatosis stage of alcoholic liver diseaseToxicol PatholYear: 20043255677615603541|
|35.||Shek FW,Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis?Eur J Gastroenterol HepatolYear: 20041621232615075983|
|36.||Arias M,Lahme B,Van de Leur E,et al. Adenoviral delivery of an antisense RNA complementary to the 3′ coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cellsCell Growth DifferYear: 20021362657312114216|
|37.||Ozawa S,Uchiyama K,Nakamori M,et al. Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomySurgeryYear: 200613945637316627068|
|38.||de Gouville AC,Boullay V,Krysa G,et al. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosisBr J PharmacolYear: 200514521667715723089|
|39.||Bueno M,Salgado S,Beas-Zarate C,Armendariz-Borunda J. Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGFJ Gene MedYear: 200681112919916958060|
|40.||Iwamoto H,Sakai H,Tada S,et al. Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesionJ Lab Clin MedYear: 19991341838910402063|
|41.||Ueki T,Kaneda Y,Tsutsui H,et al. Hepatocyte growth factor gene therapy of liver cirrhosis in ratsNat MedYear: 199952226309930873|
|42.||Halder SK,Beauchamp RD,Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosisExp Cell ResYear: 200530712314615922743|
|43.||Inagaki Y,Kushida M,Higashi K,et al. Cell type-specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in miceGastroenterologyYear: 200512912596816012952|
Keywords: liver fibrosis, gene therapy, Smad7, urokinase plasminogen activator.
Previous Document: The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mous...
Next Document: Intrascleral outflow after deep sclerectomy with absorbable and non-absorbable implants in the rabbi...